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Abstract
Human malaria is a complex disease that can show a wide array of clinical
outcomes, from asymptomatic carriage and chronic infection to acute disease
presenting various life-threatening pathologies. The specific outcome of an
infection is believed to be determined by a multifactorial interplay between the
host and the parasite but with a general trend toward disease attenuation with
increasing prior exposure. Therefore, the main burden of malaria in a
population can be understood as a function of transmission intensity, which
itself is intricately linked to the prevalence of infected hosts and mosquito
vectors, the distribution of infection outcomes, and the parasite population
diversity. Predicting the long-term impact of malaria intervention measures
therefore requires an in-depth understanding of how the parasite causes
disease, how this relates to previous exposures, and how different infection
pathologies contribute to parasite transmission. Here, we provide a brief
overview of recent advances in the molecular epidemiology of clinical malaria
and how these might prove to be influential in our fight against this important
disease.
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Background
Malaria is caused by the mosquito-transmitted protozoan 
parasite Plasmodium spp. There are five species known to infect 
humans: P. falciparum, P. vivax, P. malariae, P. ovale, and 
P. knowlesi, of which P. falciparum malaria is the most virulent 
form, causing the most morbidity and mortality in humans, and 
thus will be the focus here. Despite continual control efforts 
over the last 50 years or more, the burden of disease is still 
substantial, and recent estimates put the annual number of 
malaria cases in the region of more than 200 million, leading to 
over 400,000 deaths, predominantly in young children living in 
sub-Saharan Africa1. The first licensed malaria vaccine (RTS,S) 
has shown limited efficacy2 and currently is introduced as only a 
pilot scheme in a few settings in sub-Saharan Africa. The main 
disease intervention therefore still relies on drug treatment of 
patients and prevention of exposure by (insecticide-treated) bed 
nets, spraying of houses with insecticides, and other general 
mosquito control measures. Following a large scale-up of vector 
control in combination with artemisinin combination therapy, 
there has been an overall reduction in the number of malaria 
cases over the last decade3. However, this reduction does 
not always correspond well with known control measures4 and 
shows significant geographic variations. For example, big 
reductions have been achieved in Southeast Asia and the 
Western Pacific, whereas several regions in the Americas and 
Africa have experienced no change or even an increase in cases 
in recent years1,5.
The challenges in malaria control are manifold, and, even in 
regions where a drastic reduction has been achieved and where 
local elimination is theoretically possible, maintaining a disease-
free state without achieving a similar reduction in neighboring 
regions will be difficult. Underlying these challenges is a lack of 
understanding of the basic biology of malaria transmission and 
its relationship to the epidemiological patterns of infection and 
disease in different transmission settings. In particular, not all 
infections cause severe clinical symptoms, and most infections 
contributing to transmission in a given location cause only 
mild illness or are classified as asymptomatic (but see 6 for a 
critical discussion on the terminology of “asymptomatic” malaria). 
Intervention-induced changes in parasite transmission therefore 
will incur shifts in the age distributions of particular age- and 
exposure-dependent disease manifestations in complex ways7,8. 
Predicting the epidemiological outcome of control measures 
therefore requires a more in-depth knowledge of the factors 
responsible for severe malaria as well as a better understanding 
of who is currently infected and who contributes to transmission.
What causes severe malaria?
Malaria infections are initiated by the bite of an infectious 
mosquito, which releases sporozoites into the bloodstream that 
subsequently travel to, and undergo differentiation into mero-
zoites in, the liver. After multiple rounds of multiplication within 
infected liver cells, merozoites are released into the bloodstream, 
starting a cycle of repeated invasion and multiplication within 
red blood cells (RBCs) that leads, both directly and indirectly, 
to considerable cell destruction. In addition to anemia as a direct 
result of RBC loss, splenic clearance of uninfected RBCs, and 
reduced RBC production, malaria pathology is often caused by 
parasites sequestering in the deep vasculature, leading to local 
inflammation, hemorrhages, tissue damage, and obstruction of 
blood flow. Sequestration itself is the result of infected RBCs 
(iRBCs) adhering to a number of different host endothelial cell 
receptors9–12 through highly polymorphic parasite proteins called 
PfEMP113 that are encoded by the var multigene family14 and 
inserted into the surface of iRBCs. The prominent expression of 
these proteins on the surface of iRBCs makes them key targets 
for adaptive immune responses, which the parasite escapes by 
exploiting the enormous sequence variation of var genes both 
between multiple variant var gene copies within individual 
parasites and between repertoires of var genes within parasite 
populations. In one of the most sophisticated immune-evasion 
strategies studied, the parasite can switch between different 
PfEMP1 types during infection in a process referred to as 
clonal antigenic variation15,16.
Despite its diversity, PfEMP1 plays a central role as a target 
of naturally acquired immunity (NAI). Over years of repeated 
infections, individuals living in malaria-endemic areas acquire a 
repertoire of PfEMP1 variant-specific immune responses through 
repeated infections that are believed to confer protection from 
life-threatening disease (reviewed in 17). In a clear illustration 
of the importance of PfEMP1 as immune targets, women in their 
first pregnancy who have grown up in malaria-endemic areas and 
who have gained immunity to severe malaria temporarily lose 
this immunity because their placentas open up a novel niche for 
parasite sequestration. This is exploited by a single functionally 
and immunologically distinct PfEMP1 type, VAR2CSA (see 
below), which is present in every parasite genome and to which 
immunity is rapidly gained18.
So far, the high diversity of PfEMP1 has precluded this fam-
ily of molecules from being considered a serious vaccine target. 
However, the discovery that certain disease manifestations are 
associated with the expression of restricted subsets of PfEMP1 
variants has opened up the debate of whether an anti-disease or 
anti-virulence vaccine in fact might be a feasible option19. One 
of the first and so far most robust examples is the involvement 
of a particular PfEMP1 variant in pregnancy-associated malaria, 
mediated by the binding of VAR2CSA-expressing iRBCs to 
placental chondroitin sulfate A (CSA)20. The fact that this 
protein appears unusually conserved is now being exploited in 
the design of the first placental malaria vaccines that are currently 
undergoing clinical tests21,22.
This functional subdivision of var genes can be extended to 
those that are involved in childhood malaria. For example, 
based on upstream promoter sequence (Ups), var genes can be 
divided into three groups—UpsA, UpsB, and UpsC—of which 
UpsA genes are frequently found to be upregulated during 
severe infection, particularly in young children. Although sequence 
diversification within this UpsA group of genes appears to be 
more restricted than others, they are still too diverse as a whole 
to be considered potential vaccine targets. As such, the recent 
discovery that a much smaller gene subset, those containing 
specific domain types called CIDRα1, and their binding to the 
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endothelial protein C receptor (EPCR) appeared to be associated 
with cerebral malaria caused great excitement23–26. In fact, 
confidence in the importance of this interaction underlying 
severe infection outcomes is such that it is now being promoted 
as a potential anti-disease vaccine target19.
However, the crux of the problem is that, in most cases, 
findings are based on observed associations between pathological 
outcomes and the proportional expression of gene variants 
within the infecting parasite population sampled from peripheral 
blood rather than directly from parasites that are sequestered 
in tissues. The issues with these kinds of studies are further 
compounded by the enormous technical challenge of fully 
taking into account individuals’ exposure histories and therefore 
their immune status at the time of infection. This means that 
caution has to be exercised when trying to infer causality, which 
was recently re-emphasized by Azasi et al., who found that 
in vitro iRBC binding to endothelial cells is often independent 
of EPCR and can easily be interrupted under flow conditions27. 
Approaches to gain a better understanding of the host–parasite 
interaction in capillaries include (1) improved understanding 
of the parasites actually responsible for pathology through 
direct sampling of sequestered parasites in different tissues by 
either using skin biopsies in patients28 or sampling from tissues 
post-mortem29; (2) improved assessment of parasite sequestration 
in tissues through direct observation of parasites within 
capillaries through mucosal surfaces to correlate capillary 
congestion with disease outcome30; (3) seeking associations 
between peripheral parasite gene expression levels and direct 
measures of sequestration through malarial retinopathy25,31; and 
(4) improved understanding of the role of NAI in shaping the 
infecting parasite population by seeking associations between 
peripheral parasite gene expression levels and pre-existing 
antibody responses in controlled human infections of volunteers 
with differing levels of natural exposure to infection32.
Who is infected and who contributes to transmission?
As the outcome of an infection is partially determined by an 
individual’s exposure history to the parasite, elucidating the 
clinical epidemiology of malaria requires an understanding of 
a region’s (spatially and time-varying) transmission intensity 
and therefore knowledge of who is currently infected, who 
contributes to transmission, and how much. However, measuring 
disease prevalence and relating this prevalence to transmission 
remain important challenges that can be severely hampered 
by the relatively high proportion of clinically silent and low- 
parasite density infections, especially in highly endemic settings. 
With the improvement of molecular methods for parasite 
detection, it has become increasingly clear that microscopy— 
still the gold standard for diagnosis in many places— 
systematically misses a large number of low-density infections. 
Microscopy detects parasite densities in the blood of greater 
than about 100 parasites per microliter, a detection threshold 
similar to that of rapid diagnostic tests, but misses an average 
of half of all malaria infections compared with standard 
polymerase chain reaction (PCR)33. Paradoxically, this appears 
to be the case regardless of transmission setting or exposure/ 
immunity, and a higher fraction of submicroscopic infections 
occur in low-transmission settings. Indeed, it has been estimated 
that in areas with less than 10% prevalence by PCR, 88% of 
infections would not be detected by microscopy33. Recent 
ultrasensitive PCR techniques34 have lowered this detection 
limit even further to 22 parasites per milliliter, which has led to 
researchers confirming the substantial reservoir of low-density 
infections. In the absence of molecular methods for routine 
surveillance, understanding the relationship between clinical 
cases (which form the basis of surveillance in most endemic 
countries) and overall prevalence of infection remains a key 
challenge.
The prevalence of infection is not the only consideration for 
defining transmission, however. Many infections are composed 
of multiple parasite clones, and new infections often occur and 
cause new episodes of disease against the backdrop of ongoing 
asymptomatic parasitemia. This means that even with accurate 
estimates of the fraction of infected people, we are still unable 
to describe the incidence or force of infection, which is related 
to the number of new infections over time. The enormous 
genomic diversity of the parasite, coupled with the frequency of 
low-density infections, makes it difficult to detect how many 
clones each infection is composed of, and there are few robust 
strain markers with which to follow chains of transmission. 
Recently, new sequencing methods and accompanying analytical 
tools have shed light on the extent of superinfection, revealing 
substantial “complexity of infection”, particularly in high- 
transmission settings like Uganda where individuals can harbor 
up to 20 clones35. One result of these findings is a move toward 
the concept of using the molecular force of infection (molFOI), 
which measures the number of new genotypes acquired by 
individuals over time36, to define transmission settings. An 
added value of these highly sensitive diagnostic tools is that 
they allow tracking of the genetic relatedness between parasites 
or infections and, with it, the identification of transmission 
chains and focal transmission areas. The latter will be particularly 
important for regions that are nearing malaria elimination 
and where the monitoring and characterization of residual 
transmission will be key for sustained malaria control.
The surveillance issues described above are all designed to 
measure asexual parasites in the blood, which cause the clinical 
manifestations of malaria but cannot be transmitted to mosquitoes. 
This means that quantifying the infectious reservoir requires 
different approaches. Only a small fraction of blood-stage 
parasites develop into male and female gametocytes, the sexual 
parasite stages that are taken up during a blood meal and 
underlie infectiousness. The molecular pathways responsible 
for the switch to sexual development and the dynamics of 
gametocytes in the body, as well as their relationship to trans-
mission, are still mysterious37. Furthermore, early notions that 
directly relate asexual parasitemia with infectivity, which implied 
that young individuals suffering from severe disease are by far 
the highest contributor to malaria transmission, have also been 
put into question by revealing that asymptomatic infections 
contribute significantly more to transmission than previously 
thought38–40. For example, a recent study in Ethiopia used 
mosquito blood-feeding experiments to establish that only 15% 
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of P. falciparum-infected individuals were infectious and that 
asexual parasitemia was not correlated with infectiousness40. 
Earlier findings that gametocytes are not homogeneously 
distributed within the blood and may cluster under the skin to 
promote transmission41,42, plus the considerable uncertainties 
associated with the determinants of parasite fitness in the 
mosquito as it transitions from sexual gametocytes to infectious 
sporozoites, mean that there are still some outstanding 
difficulties in quantitatively linking standard measures of 
prevalence with transmission intensity.
Going forward
The identification of EPCR-binding phenotypes and their 
potential involvement in cerebral malaria has caused excitement 
and raised some optimism about the possibility of developing an 
anti-disease vaccine. However, for a convincing case to be made, 
one still needs to unambiguously demonstrate the causal link 
between host receptor binding and specific disease manifestations. 
A crucial point here is that every parasite contains in its rep-
ertoire most, if not all, of these “disease-causing”, or rather 
disease-associated, variants. That is, if the parasite has the 
freedom to express its entire PfEMP1 antigenic repertoire 
during infection, what determines the actual outcome? It has been 
shown that PfEMP1 expression is hierarchical43,44 and that host 
immune responses have an influence on what variants are 
expressed during infection32,45. However, this alone cannot explain 
why an infection causes cerebral malaria in one child but severe 
malarial anemia in another. Furthermore, the observed hierarchical 
expression of var genes may be due simply to the existence of 
alternative molecular strategies used by the parasites to evade 
immune responses in individuals of different levels of immu-
nity. There are reported examples of asymptomatic infections 
that exhibit high levels of expression of group A-like var genes 
previously found to be associated with severe malaria, which 
suggests that the PfEMP1 antigens they encode can play a role 
in the maintenance of chronic infections46. At this point, more 
integrated (that is, systems and -omics) approaches should be 
able to offer more detailed information about the specific 
immunological and parasitological processes involved in the 
progression toward disease, especially when taking into 
consideration the composition of the infecting parasite popula-
tion in relation to the host’s immune history (see 47 and 48 for 
recent examples).
More advanced approaches are also required for improving our 
understanding of NAI to malaria. Crucially, this necessitates 
(1) a clear definition of what constitutes protection and (2) robust 
and measurable correlates of protection, neither of which are 
straightforward. As mentioned above, NAI has to be considered 
as a multi-stage process or even a continuum whereby infection 
severity generally attenuates with cumulative exposure to 
infection. Numerous studies have tried to find correlates of 
protection by means of prospective cohort studies in which 
individuals’ immune responses to predefined panels of antigens 
are correlated with the incidence of clinical episodes. One of 
the main problems with these studies is the often small effect 
size, leading to contradictory findings and poor reproducibility 
(reviewed in 49). This is further complicated by the lack of 
reliable measures of how often an individual has been 
challenged in the past, which is an essential consideration given 
that the needle of protective responses and the haystack of 
non-protective responses, as well as NAI itself, all increase with 
cumulative exposure to infection. Furthermore, condensing this 
multifaceted process into a binary phenotype (protected or not) 
bypasses some of the aforementioned complexities underlying 
malaria pathology and NAI and thus is unlikely to provide a 
comprehensive picture of the myriad of processes involved.
In that respect, it is also imperative to embrace more sophisticated 
methods to analyze increasingly complex datasets. Machine 
learning approaches offer a number of advantages over more 
traditional, univariate analyses in their ability to extract 
non-linear relationships and interactions from high-dimensional 
data in a hypothesis-free manner. For example, in a recent study, 
we used a machine learning approach to identify predictive 
signatures of clinical protection from protein microarray 
data containing thousands of measured immune markers50. In 
another study, Helb et al. used a predictive framework based on 
machine learning to estimate recent exposure to the malaria 
parasite51. However, these powerful methods crucially rely on 
detailed and robust datasets that permit appropriate cross- 
validation and verification of research findings. One important 
step forward in that direction is the use of ensemble datasets 
across a wide range of studies, as was recently advocated in 
order to better define the infectious reservoir and measure 
transmission more accurately52.
Finally, a more improved understanding of the biology of 
mosquito–human and human–mosquito transmission needs to 
include better knowledge of local vector ecologies. Surprisingly, 
we still know relatively little about how changes in mosquito 
abundance and species distributions over the last few years 
and decades—some of the most important determinants of 
malaria epidemiology—might have not only influenced but 
actively shaped some of the observed changes in malaria 
incidence. Unfortunately, detailed and long-term surveillance 
data on vector distribution are scarce and are available for only 
a small number of vector species and epidemiological settings. 
Therefore, large-scale vector sequencing initiatives, such as 
the malariaGEN 1000 genomes project53, together with more 
detailed investigations into the behavioral and ecological factors 
underlying this part of the transmission cycle, will have a 
central role to play in developing a fine-grained and holis-
tic understanding of malaria epidemiology that incorporates 
the Plasmodium parasite, the human host, and the mosquito 
vector.
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